VAQTA Injection

Hepatitis A Vaccine (HAV Antigen)
50 U/Dose
Merck Sharp & Dohme B.V.
Pack size 1 Dose (1ml) Vial
Dispensing mode POM
Source NETHERLANDS
AgentCITY MEDICAL STORE
Retail Price 158.00 AED

Available as:

Indications

VAQTA Injection is used for: Active immunisation against Hepatitis A virus

Adult Dose

Intramuscular Active immunisation against hepatitis A Adult: 2-dose vaccination series: 1 mL IM; separate the 2 doses by 6-12 months

Child Dose

Intramuscular Active immunisation against hepatitis A Child: Indicated as routine vaccination for children at least 12 months of age (ACIP guidelines) <12 months: Not indicated Routine vaccination (2-dose series): 0.5 mL IM initiated at aged 12 through 23 months; separate the 2 doses by 6-12 months Children who have received 1 dose before age 24 months, should receive a second dose 6-12 months after the first dose Catch up schedule For any person >2 yr who has not already received hepatitis A vaccine series, give 2 doses separated by 6-18 months if immunity against hepatitis A virus infection is desired Minimum interval between the 2-dose series is 6 months

Renal Dose

Administration

Contra Indications

Hypersensitivity. Vaccines prepared in egg cultures are contraindicated in patients with hypersensitivity reactions to egg. Severe immunodeficiency. Malignant disease being treated with chemotherapy or radiotherapy and for at least 6 mth after stopping treatment. Patients with compromised immune system such as those on high-dose systemic corticosteroids, immunosuppressants or HIV positive.

Precautions

Alcohol or disinfectant used for cleaning the skin prior to inj should be allowed to evaporate completely before vaccination to prevent vaccine inactivation. Lactation: not established

Pregnancy-Lactation

Interactions

Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.

Adverse Effects

Side effects of Hepatitis A Vaccine (HAV Antigen) : >10% Injection site tenderness (3-56%), erythema (1-22%), warmth (1-17%), swelling (9-11%), Irritability (11-36%), Anorexia (1-19%), Drowsiness (15-17%), Headache (1-16%), Fever > 100.4 F (9-11%) 1-10% URI (1-10%), Otitis media (8%), Rhinorrhea (6%), Diarrhea (1-6%), Cough (1-5%), Rash (1-5%), Weakness/fatigue (4%), Vomiting (1-4%), Fever > 102 F (3%), Crying (2%) <1% Hematoma, Incr. CPK, Photophobia, Vertigo Potentially Fatal: Anaphylaxis.

Mechanism of Action

Hepatitis A antigen is prepared from formaldehyde-inactivated hepatitis A virus grown in human diploid cells. It is used for active immunisation against hepatitis A infection.

Note

VAQTA 50 U/Dose Injection manufactured by Merck Sharp & Dohme B.V.. Its generic name is Hepatitis A Vaccine (HAV Antigen). VAQTA is availble in United Arab Emirates. Farmaco UAE drug index information on VAQTA Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Hepatitis A Vaccine (HAV Antigen) :